HC022

HC022 is a monoclonal antibody developed by Shanghai Hongcheng Pharmaceutical Co. Ltd. (also referenced as HC Biopharma) for the treatment of systemic lupus erythematosus and cutaneous lupus erythematosus. It acts as an immunomodulator, though the precise molecular target has not been publicly disclosed. The drug is currently in early clinical development, with phase 1 trials planned to assess its safety, tolerability, pharmacokinetics, and immunogenicity following subcutaneous administration in healthy volunteers[1][2][3][4][5]. As of late 2024 and early 2025, no orphan drug designation or regulatory approval has been granted.